ProQR Therapeutics N.V.
Close on Oct 19, 2026
About ProQR Therapeutics
Pharmaceutical Preparations, SIC 2834
ProQR Therapeutics N.V. is a biopharmaceutical company that discovers and develops therapies using an RNA editing technology platform. The company focuses on advancing preclinical and clinical development programs, including investigational RNA-targeted product candidates such as ultevursen and sepofarsen. Rather than selling commercial treatments directly to end users, ProQR works in collaboration with global pharmaceutical companies, research organizations, and patient foundations. Its partners include Eli Lilly and Company, the Rett Syndrome Research Trust, and the Foundation Fighting Blindness.
The company maintains its corporate headquarters, principal executive offices, and laboratory facilities in Leiden, the Netherlands. Its corporate structure encompasses several entities located in the Netherlands and the United States, including ProQR Therapeutics I Inc. The organization carries out research and clinical testing across geographic regions subject to supervision by health authorities, including the United States Food and Drug Administration and the European Medicines Agency.
Summary of the business section of ProQR Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ProQR Therapeutics N.V.
- Founded
- 2012
- Headquarters
- Leiden, Netherlands
- Address
- Zernikedreef 9
- Phone
- 31 88 166 7000
- Employees
- 59, Dec 31, 2014
- Industry
- Pharmaceutical Preparations
- Incorporated in
- P7
- Fiscal year ends
- December 31
- Auditor
- KPMG Accountants N.V., Amstelveen, the Netherlands
Stock & identifiers
- Ticker
- PRQR
- Exchange
- Nasdaq
- IPO date
- Sep 19, 2014
- Shares outstanding
- 105M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1612940
- CUSIP
- N71542109
- ISIN
- USN715421095
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Boer Daniel Anton de | Chief Executive Officer, Director | 500,000 |
| Gerardus Johannes Platenburg | Chief Scientific Officer, Director | 824,388 |
| Dennis Hom | Chief Financial Officer | – |
| Bart Filius | Director | 300,000 |
| Gylvin Lykke Hinsch | Director | – |
| Alison Frances Lawton | Director | – |
| Martin Alexander Maier | Director | – |
| Theresa Heggie | Director | 43,623 |
| Domenico Valerio | Director | 725,692 |
| Begona Carreno-Gomez | Director | – |
| James Samuel Shannon | Director | 61,538 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 3, 2014 | Name change | Name changed from ProQR Therapeutics B.V. to ProQR Therapeutics N.V. |
| Sep 19, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 16, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |